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Nonsteroidal anti-inflammatory drugs (NSAIDs) have been 
demonstrated to reduce cancer rates in oesophagus, stom­
ach and colon of humans and animals. Earlier, we showed 
that high human gastrointestinal tissue levels of glutathione 
S-transferase (GST), a family of detoxification enzymes 
consisting of class a, (X, % and 0 isoforms, were inversely 
correlated with cancer risk. We investigated whether the 
NSAIDs indomethacin, ibuprofen, piroxicam, acetyl sali­
cylic acid (ASA), and sulindac, supplemented in the diet 
for 2 weeks at 25, 400, 400, 400, and 320 ppm, respectively, 
influenced gastrointestinal GSTs in male Wistar rats. In 
cytosolic fractions of oesophagus, stomach, intestine and 
liver, GST activity towards 1-chloro-2,4-dinitrobenzene was 
measured, GST isozyme levels were determined by densito- 
metrical analysis of Western blots after immunodetection 
with monoclonal antibodies, and glutathione levels were 
determined by HPLC. GST activity and GST p, levels were 
increased (1.2-1.8X) in oesophagus and small intestine by 
indomethacin, ibuprofen, piroxicam and sulindac. GST a  
levels were induced (1.2-2.8 x ) in stomach by piroxicam, 
in small intestine by indomethacin, ibuprofen, piroxicam 
and sulindac, and in liver by piroxicam. GST %  levels were 
raised (1.9-3.6X) in stomach by ibuprofen, ASA, and 
sulindac, and in small intestine by indomethacin, piroxicam, 
ASA, and sulindac. Glutathione levels were raised (1.2- 
2.3 X) by indomethacin and ASA in small intestine and by 
piroxicam in oesophagus. Enhancement of GSTs in the 
upper part of the digestive tract, resulting in a more efficient 
detoxification, may explain in part the anticarcinogenic 
properties of NSAIDs. 
Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs*) are among the 
most prescribed drugs worldwide. They have anti-inflammatory, 
analgesic, and antipyretic activities. They are used clinically for 
the treatment of patients with (e.g.) acute and chronic rheumatoid 
arthritis, osteoarthritis, ankylosing spondylitis, gouty arthritis, 
bursitis, tendositis, and inflammatory arthritis ( 1).
In addition to their therapeutic use, there is strong epidemio­
logical evidence that NSAIDs may have anticarcinogenic 
effects in humans. Sulindac caused regression of adenomatous 
polyps in patients with familial adenomatous polyposis (FAP) 
(2-4 ), whereas no effect on sporadic colonic polyps was found 
(5). Epidemiological studies suggest that regular, prolonged
* Abbreviations: NSAIDS, nonsteroidal anti-inflammatory drugs; GST, gluta­
thione S-transferase; ASA, acetyl salicylic acid; FAP, familial adenomatous 
polyposis.
use of aspirin-based NSAIDs may reduce the risk of develop­
ment and mortality of oesophageal, gastric, colonic, or rectal 
cancer (6-9), although in one prospective study no support for 
such an association was found (10). Several NSAIDs are 
currently evaluated in clinical trials. Effects of NSAIDs on 
neoplastic growth in the colon of animals and humans, includ­
ing possible mechanisms involved, were recently reviewed 
(11,12).
Many animal studies have revealed significant protection 
against development of chemically induced cancers by treat­
ment with NSAIDs. Ibuprofen inhibited carcinogenesis in rat 
colon (13), mouse forestomach and lung (14). Indomethacin 
inhibited tumorigenesis in rat colon (15-19), stomach (16,20), 
mammary gland (21), urinary bladder (22,23), and liver (24,25), 
as well as in mouse oesophagus (26,27). Piroxicam reduced 
tumour incidence in the colon (13,15,17-19,28-31), small 
intestine (18), and liver (25) of the rat. Dietary acetyl salicylic 
acid inhibited carcinogenesis in rat colon (32-34) and bladder 
(35), whereas sulindac reduced tumour multiplicity in the rat 
colon (36) and mouse forestomach (14).
A generally accepted mechanism of action of NSAIDs is 
the inhibition of cyclooxygenases, the rate-limiting enzymes 
that catalyse the formation of prostaglandin precursors from 
arachidonic acid (12,37). Prostaglandins play a role in the 
control of cell proliferation and regulation of immune functions 
(38-41). However, doses of NSAIDs required to suppress 
inflammation may exceed substantially the doses necessary to 
inhibit prostaglandin synthesis, suggesting that the anti­
carcinogenic properties of these drugs may be achieved through 
additional unidentified mechanisms (42).
Inhibitors of carcinogenesis often have an enhancing effect 
on carcinogen detoxification systems such as glutathione 
S-transferases (GSTs; EC 2.5.1.18) (43-45). The soluble gluta­
thione S-transferases are a gene family of dimeric enzymes 
comprised of four classes: a, (i, n  and 0 (43,44). They catalyse 
the binding of a large variety of electrophiles to the sulphydryl 
group of glutathione (GSH). Since most reactive ultimate 
carcinogenic forms of chemical carcinogens are electrophiles, 
GSTs take considerable importance as a mechanism for carcino­
gen detoxification (43,44). Enhancement of the activity of this 
system may result in a more efficient elimination of carcinogens 
and may ultimately lead to the prevention of cancer.
The present study was designed to investigate the effects of 
dietary administration of indomethacin, ibuprofen, piroxicam, 
acetyl salicylic acid and sulindac on glutathione and glutathione 
S-transferases in the rat oesophagus, intestine, stomach and 
liver.
Materials and methods
Animal treatment
Forty-eight male Wistar rats (183±2 g; Central Laboratory Animal Centre, 
University of Nijmegen, The Netherlands) were housed in pairs on wooden 
shavings in macrolon cages, maintained at 20-25°C and 30-60% relative 
humidity. A ventilation rate of seven air cycles/h and a 12 h light/dark cycle
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were used. The rats were randomly assigned to one of the dietary treatment 
groups. All groups were fed powdered RMH-TM lab chow (Hope Farms, 
Woerden, The Netherlands) from the same batch. After acclimatization for 7 
days the animals were fed either the basal diet (control group) or one of the 
five experimental diets. Food and water were available ad libitum. Food cups 
were replenished every 2-3 days. Food consumption and gain in body weight 
were recorded daily.
Diets
Selection of NSAIDs as well as feeding period and dose levels were based 
on studies by others, showing reduction of tumour incidence in humans and 
inhibition of chemically induced carcinogenesis in animal models, where 
NSAIDs were adjusted 2 weeks prior to carcinogen treatment (13,18,21,32,36). 
The following six diet groups (eight animals per group) were studied: (a) 
RMH-TM lab chow only or supplemented with (b) 25 ppm indomethacin, (c) 
400 ppm ibuprofen, (d) 400 ppm piroxicam, (e) 400 ppm acetyl salicylic acid, 
or (f) 320 ppm sulindac. The NSAIDs were purchased from Sigma Chemical 
Company, St Louis, MO, USA. A food processor was used to obtain a 
homogenous mixture of test compound and powdered lab chow. After receiving 
the diets for 2 weeks the rats were killed by decapitation. The study protocol 
was approved by the local ethical committee for animal experiments of the 
University of Nijmegen.
Tissue preparation
All handlings were performed on ice. After decapitation, oesophagus, stomach, 
intestine (proximal, middle, and distal small intestine and colon) and liver 
were excised immediately. Intestine and stomach were slit longitudinally and 
the contents were removed by washing with cold buffer A (0,25 M saccharose, 
20 mM Tris, 1 mM dithiothreitiol, pH 7.4). The organs were directly frozen 
in liquid nitrogen and stored at -20°C until use. For preparation of the 
cytosolic fraction the tissue was thawed quickly using cold running water, 
The mucosal surface of stomach and intestine was collected by scraping with 
a scalpel and was homogenized in buffer A (4 ml/g tissue) in a glass/glass 
Potter-Elvehjem tube. The liver was homogenized in buffer A (4 ml/g tissue) 
with 10 strokes at 1000 rpm of a motor-driven glass/Tefion homogenizer 
(Braun, Germany). The homogenate was centrifuged at 9000 g (4°C) for 
30 min. The resulting supernatant fraction was transferred to an ultracentrifuge 
tube and spun at 150000 g (4°C) for 60 min. The oesophagus was homogenized 
in 5 ml buffer A per gram tissue in a glass/glass Potter-Elvehjem tube. These 
homogenates were centrifuged at 150 000 g for 60 min (4°C). Aliquots of the 
150 000 g supernatant, representing the cytosolic fraction» were frozen in 
liquid nitrogen and stored at -20°C.
Assays
Protein concentration was assayed in quadruplicate by the method of Lowry 
et al (46) using bovine serum albumin as the standard. GST activity was 
determined in triplicate according to Habig et a i  (47), using 1-chloro-2,4- 
dinitrobenzene (CDNB) as substrate. GST isoenzyme levels were determined 
as described before (45). In short, cytosolic fractions were subjected to sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (11% acrylamide, w/v), 
and subsequently to Western blotting, using a semi-dry blotting system 
(Novablot II, Pharmacia, Uppsala, Sweden). Western blots were incubated 
with monoclonal antibodies against human GST class a  (48), |x (49), and jc 
(50). Class a  antibodies react with raL GST subunit 1, class |! antibodies 
recognize rat GST subunits 3 and 4, and class 7t antibodies react with rat GST 
subunit 7 (45). The specific binding of the monoclonal antibodies to the 
isoenzymes was demonstrated by incubation with the secondary antibody 
peroxidase-conjugated rabbit anti-mouse immunoglobulin (Dakopatts, 
Glostrup, Denmark) and subsequent development of the peroxidase label 
with 4-chloro-l-naphthol and hydrogen peroxide. Staining intensity on the 
immunoblots was quantified using a laser densitometer (Ultroscan XL, LKB, 
Bromma, Sweden). Known amounts of purified GSTs were run in parallel 
with the experimental samples and served as standards for the calculation of 
the absolute amounts of the isoenzymes in the cytosolic fractions. Total 
glutathione was quantified by high performance liquid chromatography after 
reaction with monobromobimane, as described before (45). In this assay, 
oxidized glutathione present is reduced by adding sodium borohydride to the 
reaction mixture.
Statistical analyses
The Wilcoxon rank sum test was used to assess statistical significance of 
differences beLween experimental and control groups: ^PCO.OS, b/ 3< 0.01
and CP < 0.005.
Results
Daily food consumption, intake of NSAIDs and gain in body 
weight are given in Table I. In the sulindac and piroxicam
groups food consumption was significantly reduced as com­
pared to the control group, whereas in the ibuprofen group the 
food consumption was induced. In the piroxicam group the 
lower food consumption was parallelled by a reduced gain in 
body weight. During the course of the experiment no changes 
in behavioral pattern of the animals were observed. In addition, 
none of the organs studied showed any macroscopical sign of 
toxicity of the dietary additive at the end of the experiment.
Table II shows the effects of the NSAIDs on GST activity 
in the organs investigated. No change in activity was found 
with acetyl salicylic acid (ASA). In the oesophagus and 
proximal small intestine (PSI), GST activity was induced 
by indomethacin (both 1.3X), ibuprofen (1.3 X and 1.2 X, 
respectively), piroxicam (1.8X and 1.2X) and sulindac (both 
1.3X). In addition, ibuprofen elevated GST activity in the 
colon (L3X).
In Tables III, IV, and V the effects of the NSAIDs on GST 
class a, JX and tc isoenzyme levels are given. In control animals 
GST a  (Table III) was undetectable in oesophagus and colon, 
low in stomach (222± 20  ng/mg protein) and high in liver 
(12282±1227 ng/mg protein) and small intestine. In middle 
small intestine (MSI), none of the diets significantly influenced 
GST a  expression. ASA did not influence GST a  levels. 
Indomethacin increased levels of GST a  in PSI and DSI (1.6X 
and 1.9 X, respectively) as compared to controls. Ibuprofen 
increased GST a  levels in PSI (1.4X), piroxicam increased 
levels in stomach, DSI and liver (1.8X, 2.8X, and 1.2X) and 
sulindac had an inducing effect on GST a  levels in DSI 
(2. IX), GST \x (Table IV) was expressed at high levels in all 
tissues examined. Parallel to GST activity, GST \i levels in 
oesophagus and DSI were modulated by the same NSAIDs: 
indomethacin (1.4X and 1.6X, respectively), ibuprofen (1.4X 
and 1.3X), piroxicam (1.6X and 1.4 X) and sulindac (1.5 X 
and 1.4X), whereas ASA did not change GST (i levels, GST 
71 (Table V) was undetectable in oesophagus and liver, and 
low in all other organs studied, ranging from 114±21 ng/mg 
protein in MSI to 568±84 ng/mg protein in PSI in control 
animals. All NSAIDs tested increased GST tc levels at one or 
more sites: indomethacin increased GST n  levels in MSI 
(2 . IX), ibuprofen in stomach (1.9X), piroxicam in both MSI 
and DSI (2.4X and 2 .8 X, respectively), ASA in stomach, MSI 
and DSI (1.9X, 3 .2 X and 1.9X, respectively) and sulindac in 
stomach and MSI (2.6X and 3.6X).
Table VI shows the effect of the NSAIDs on the GSH 
content in the organs studied. Gastric, colonic and hepatic 
GSH contents were not influenced by any of the NSAIDs 
tested. Elevation of the GSH content was seen by indomethacin 
in PSI, MSI and DSI (1.2X, 2 .3 X and 2.3 X, respectively), by 
piroxicam in oesophagus (1.6 X), and by ASA in MSI (1.6X).
Discussion
In the present study we have demonstrated that NSAIDs are 
able to induce glutathione S-transferases, especially in the 
upper part of the rat digestive tract.
During the last decade, many studies have shown significant 
protection against the development of cancer by NSAIDs. 
Compelling evidence is presented in several epidemiological 
studies, suggesting that NSAIDs have significant protective 
activity against human oesophageal, gastric, and colonic cancer 
(11,12). Regression of colon adenomas during treatment with 
NSAIDs, particularly sulindac, occurred in patients with famil­
ial adenomatous polyposis coli who are at high risk for
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Table I. Daily food consumption, NSAID-intake and gain in body weight of male Wistar rats receiving diets supplemented with indomethacin, ibuprofen, 
piroxicam, ASA or sulindac
Treatment group 
(n =  8)
Dose
(ppm)
Food consumption 
(g/day)
Total NSAID-intake 
(mg/day/kg b.
Gain in body weight 
(g/day)
Control .  _ 16.1 ±0.3 2.4±0.2
Indomethacin 25 15.9+0.5 2 .0 ± 0.1 2.5±0.3
Ibuprofen 400 17.0±0.2a 34.0±0.5 2.3±0.2
Piroxicam 400 14.7+0.3« 29.4+0.5 1.2 ± 0 .2 b
ASA 400 16.3±0.5 32.7+0.4 2 .6 ± 0.1
Sulindac 320 14.8±0.3a 29.6 ±0.7 1,8 + 0,2
Values given are means ±SEM. The one-tailed Wilcoxon rank sum test was used to assess statistical significance of differences between control and treated 
groups. aP<0.05, and bP<0.01,
Table II. Effects of indomethacin, ibuprofen, piroxicam, ASA or sulindac on rat alimentary tract glutathione S-transferase activity
Treatment group
(n = 8)
Glutathione S-transferase activity (nmol/min.mg protein)
oesophagus stomach PSI MSI DSI colon liver
Control 49±5 184±25 363 ±29 134±12 59±7 41±3 1817 ± 152
Indomethacin 66±5b 146+15 473±33a 173 ±11 54±5 45 ± 4 1708 ± 155
Ibuprofen 63+6a 164±2 446±34a 134±7 49 ±4 -4 a 1593 ±269
Piroxicam 88±7C 157+16 452±33a 152± 13 59±4 47 ± 4 2160± 151
ASA 45±5 166± 13 406 ±28 138±11 50±3 43±6 1593 ±87
Sulindac 63+4a 152± 17 472±35a 147 ±12 50±4 43 ± 4 1598 ±156
PSI, proximal small intestine; MSI, middle small intestine; DSI, distal small intestine; aP<0.05, bP<0.01, and CP < 0.005.
Table III. Effects of indomethacin, ibuprofen, piroxicam, ASA or sulindac on rat alimentary tract glutathione S-transferase a  levels
Treatment group
in = 8)
Glutathione S-transferase a  level (ng/mg protein)
oesophagus stomach PSI MSI DSI colon liver
Control ND 222 ± 2 0 4705 ±753 2780±453 734+175 ND 12282±1227
Indomethacin ND 308+79 7378±874a 3322 ±509 1389±331n ND 11774±567
Ibuprofen ND 252±15 6547+499a 2849 ±643 974± 131 ND 13614±2399
Piroxicam ND 400+543 6413 ±662 2783 ±346 2028+447b ND 14-817 ±  1158a
ASA ND 288+36 5741 ±659 2682±386 951 +  165 ND 10267 ±676
Sulindac ND 241 ±29 5694±300 3459 ±1043 1526±153b ND 11306 ±897
ND, Not detectable; a/><0.05, and bP<0.01.
Thble IV. Effects of indomethacin, ibuprofen, piroxicam, ASA or sulindac on rat alimentary tract glutathione S-transferase \x levels
Treatment group 
(» = 8)
Glutathione S-transferase |i level (ng/mg protein)
oesophagus stomach PSI MSI DSI colon liver
Control 3469 ±326 32771 +  1768 8112 ±  1037 6839±774 4891 ±684 4567 + 291 31662 _ 5467
Indomethacin 4738+3431’ 30755±2787 129l8 + 1334a 7581±873 5644±639 5178±744 37877 _ 3352
Ibuprofen 4792±268a 39165+2641 10582+870a 6313 ±993 5907 ±676 4598+637 33416 _ 5832
Piroxicam 5432+356c 34470+1926 11740±1065a 6859±789 6526 ±420 4691 ±240 32393 _ 2267
ASA 4008 ±399 37763 ±1268 9227 ±1338 6153±804 5432+676 5650±751 28760 4384
Sulindac 5223±461c 34591+813 11263 ± 1027a 6975 ± 8  97 6289±785 5500±791 25555 _ 4719
aP<0.05, bP<0.01 and CP<0.005.
development of colonic cancer (2-4). NSAIDs such as aspirin, 
indomethacin, piroxicam, and sulindac were repeatedly shown 
to inhibit chemically induced tumours of the colon (15,17- 
19,29-31,51-53), oesophagus (26,27), bladder (54), breast 
(21), and liver (24) in laboratory animals.
Several hypotheses have been proposed to explain the 
mechanism of chemoprevention by NSAIDs: (a) NSAIDs 
reduce the gastrointestinal permeability of carcinogens and
their metabolites (55), (b) NSAIDs are scavengers of reactive 
oxygen species involved in initiation and promotion of cancer 
(56), (c) NSAIDs can bind to cytochrome P450-monooxygen- 
ases, thereby inhibiting P450-mediated activation of procarci- 
nogens to reactive electrophilic intermediates (57,58), On the 
other hand, ibuprofen and indomethacin are able to induce 
prokaryotic cytochrome P450BM_3 (CYP102) (59). (d) In paral­
lel with the inhibition of tumour growth, aspirin, indomethacin,
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Table V. Effects of indomethacin, ibuprofen, piroxicam, ASA or sulindac on rat alimentary tract glutathione S-transferase n levels
Treatment group Glutathione S-transferase tc level (ng/mg protein)
(«“ 8 ) oesophagus stomach PSI MSI DSI colon liver
Control ND 240±39 568±84 114±21 125+50 238±51 ND
Indomethacin ND 306±87 542 ±44 234+39b 262+98 328 ±48 ND
Ibuprofen ND 464±51c 642 ±46 188 ±55 156+32 257±23 ND
Piroxicam ND 397 ±89 590±59 278±67b 356±89b 247 ±24 ND
ASA ND 447±95a 599±59 368 + 105b 236+54a 318±30 ND
Sulindac ND 616±27C 554±73 415±72c 249±58 268 ±47 ND
ND, Not detectable; aP<0.05, bP<0.01, and CP<0.005.
Tabic VI. Effects of indomethacin, ibuprofen, piroxicam, ASA or sulindac on rat alimentary tract glutathione levels
Treatment group
(n= 8 )
Glutathione (ng/mg protein)
oesophagus stomach PSI MSI DSI colon liver
Control 18.1 ± 1.6 24.8±2.1 12.2±1.9 3,8±0.8 2.4+0.5 8.8 ±2.9 39.2±2.9
Indomethacin 24.5 ±3.4 26.5±2.5 15.1 ±1.4° 8 .6 ± l . l c 5.6±0.6C 7.5±2.8 40.8±6.9
Ibuprofen 20.1 ± 1,6 27.3±3.3 13.9 ± 0.8 4.4±0.9 1.5 ±0.3 7.6±2.6 45.9±6.9
Piroxicam 28.2+3.l b 27.0±2.9 15.2± 1.8 5.4±L4 2.3±0.3 6,5±1.7 51.2±6.Q
ASA 16.6±1.4 25.3±2.0 12,3 ±1*5 6.0±0.9a 1.5+0.2 6.7±2.4 37.0±3.5
Sulindac 17.8±1.2 19.0±1.9 13,9±1.7 5.9±1,1 1.3 ±0.1 4.8 ±1.6 46.1 ±3.7
aP<0.05, b/»<0.01, and CP<0.005.
and piroxicam, reduce the prostaglandin levels in the colon of 
rodents treated with carcinogens (15,17,60), by inhibition of 
cyclooxygenases, the rate-limiting enzymes in the synthesis of 
prostaglandins (61,62). On the other hand, GSTs are involved 
in the synthesis of prostaglandin D2, E2 and F2ot (63). (e) 
NSAIDs can inhibit the induction of ornithine decarboxylase 
activity and tissue levels of putrescine, two markers of tumour 
promotion (64,65). (f) In addition, NSAIDs may inhibit the 
activity of enzymes such as phosphodiesterases or cyclic GMP- 
AMP protein kinases (66), which may be central to cancer 
initiation and promotion.
Much of the research on NSAIDs and cancer prevention at 
this moment is focused on the hypothesis that prostaglandins 
may play a key role in the regulation of neoplasia. However, 
there is no direct evidence that NSAIDs prevent tumour 
development solely through inhibition of cyclooxygenases 
(67), and prevention of cancer could be due to multiple 
mechanisms. Another way of action of NSAIDs, in addition
*
to the possibilities cited above, may be the enhancement of 
carcinogen detoxification by GSTs, as shown in this study. A 
more efficient detoxification could lead to a reduction of 
biologically active compounds and thus prevent carcinogenesis. 
No information about the possible effects of NSAIDs on 
oesophageal, gastric, intestinal, and hepatic GST enzyme 
activity has been reported before. In our study, GST activity 
in the oesophagus and proximal small intestine was increased 
by indomethacin, ibuprofen, piroxicam, and sulindac* This 
may be of direct significance in the protection against cancer 
in these organs. However, organs such as the colon could also 
benefit from a more efficient detoxification in the upper part 
of the digestive tract, since lower levels of carcinogens may 
now reach the colon.
In human organs at high risk for cancer development low 
GST levels were measured, and vice versa (68). Recent data, 
mostly obtained from animal studies, have indicated that many 
naturally occurring dietary anticarcinogens are able to elevate
the levels of GSTs (44,45, and references therein). Enhance­
ment of GSTs in humans was found after consumption of 
cruciferous vegetables with cancer preventing properties such 
as broccoli and Brussels sprouts (69,70) and a reduction 
of oxidative DNA damage in humans was measured after 
consumption of brussels sprouts (71). In this respect the 
chemopreventive properties of NSAIDs could very well be 
mediated in a similar way by the enhancement of GSTs,
In addition to the measurement of GST activity, it may be 
important to register changes in the levels of GST isoenzymes, 
which have different though partly overlapping substrate speci­
ficities. The isoenzymes showed a tissue specific distribution. 
Class a  GSTs are abundant in liver and small intestine, whereas 
class Pi GSTs are present in stomach, small- and large intestine 
(43,45). In contrast, class (i enzymes seem to be less organ 
specific since they were detected at high levels in all tissues 
examined. GST a  was not detectable in the oesophagus and 
colon, and GST % was undetectable in both oesophagus and 
liver and none of the NSAIDs had any effect on this. The 
increase in GST activity in oesophagus and PSI by indometh­
acin, ibuprofen, piroxicam and sulindac was parallelled by a 
rise in GST [i level in the same order of magnitude. This was 
expected, since GST [i is the most prominent of all GSTs in 
the rat (Tables III-V). In two of the sites in which both GST 
activity and GST |i levels were induced, GST a  level was 
increased as well. The molecular basis for these inductions is 
not clear yet.
Indomethacin, ibuprofen, piroxicam, and sulindac each 
induced the GST enzyme activity as well as GST a, GST |ll 
or GST Ti levels in at least one organ. Indomethacin, ibuprofen 
and sulindac were equally efficient in inducing glutathione 
S-transferases, in seven out of 28 possibilities (25%). Piroxicam 
appeared to be the most active, with inductions seen in 32% 
of all possibilities. Acetyl salicylic acid showed an increase 
of glutathione S-transferase enzyme activity or isoenzyme 
levels in only 11% of all possibilities, which makes it the least
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active form of the NSAIDs tested. The amount of NSAIDs 
consumed by the rats in our study (2-35  mg/day/kg b.w.) 
matches very well with doses prescribed to patients suffering 
from rheumatic diseases (3-100 mg/day/kg b.w.; see Table I), 
suggesting that the effects of NSAIDs on GSTs as found in 
rats may be achieved in humans as well, NSAIDs have side- 
effects in both humans as well as animals. We observed a 
decreased food consumption in the piroxicam and sulindac 
groups. In these animals, however, none of the organs showed 
any macroscopical sign of toxicity at the end of the experiment, 
suggesting that the induction of GSTs are not the consequence 
of toxic effects of these NSAIDs. This is further supported by 
the observation that ibuprofen induced food consumption as 
well as GST activity and isoenzymes.
No data on the effects of the NSAIDs tested on GSH levels 
have been reported before. GSH is an important physiological 
nucleophile which is coupled with reactive electrophiles such 
as carcinogenic nitrosamines (45), catalysed by the glutathione 
S-transferases. Significantly increased levels of GSH, however, 
were found in only five out of 35 possibilities: in small 
intestine by indomethacin, in oesophagus by piroxicam and in 
MSI by ASA. In PSI and oesophagus, this increase in GSH 
level parallelled an induction of GST activity.
In conclusion, our data demonstrate that NSAIDs are able 
to elevate the detoxification potential of tissues from the 
gastrointestinal tract, by increasing the expression of GSTs. 
This seems to be a common working mechanism in the 
prevention of carcinogenesis.
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